Table 2.

(a,b) Diagnostic performance of KRAS detected in plasma as compared to KRAS detected in tissue.

(a)
	Tissue KRAS
	WT		Mutated		Value (95% CI)
Plasma KRAS
WT	9 (14.5%)		4 (6.5%)		Cohen’s K: 0.43 (0.17–0.68)
Mutated	9 (14.5%)		34 (54.8%)		Sensitivity: 89.5% (75.2–97.1%)
					Specificity: 50.0% (26.0–74.0%)
Not Informative	3 (4.8%)		3 (4.8%)		PPV: 79.1% (70.2–85.9%)
					NPV: 69.2% (44.4–86.4%)
(b)
	Tissue KRAS
	Cd12	Cd13	Cd146	WT	Concordance
Plasma KRAS
Cd12	28 (45.2%)	1 (1.6%)	0	9 (14.5%)	Kappa: 0.54 (95% CI: 0.33–0.75); % agreement: 75%
Cd13	0	4 (6.5%)	0	0
Cd146	0	0	1 (1.6%)	0
WT	3 (4.8%)	1 (1.6%)	0	9 (14.5%)
Not Informative	3 (4.8%)	0	0	3 (4.8%)